Regeneron Pharma Is Maintained at Outperform by RBC Capital
Regeneron Pharmaceuticals Analyst Ratings
RBC Lifts Price Target on Regeneron Pharmaceuticals to $1,260 From $1,252, Keeps Outperform Rating
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,054,060, According to a Recent SEC Filing
Market Whales and Their Recent Bets on REGN Options
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
Declining Stock and Solid Fundamentals: Is The Market Wrong About Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)?
$100 Invested In This Stock 5 Years Ago Would Be Worth $400 Today
Erste Group Downgrades Regeneron Pharmaceuticals(REGN.US) to Hold Rating
Barclays Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,220
Regeneron Pharma, Super Micro Computer And Global Payments Are Among Top 10 Large Cap Losers Last Week (Sept 23-Sept 27): Are The Others In Your Portfolio?
Novo Nordisk's Ozempic, Regeneron/Sanofi's Dupixent Set to Advance in Top Drug Sales
Notable Analyst Calls This Week: Microsoft, Starbucks and GM Among Top Picks
Jim Cramer on Regeneron Pharmaceuticals Inc. (REGN): 'Leerink Analysts Downgraded Regeneron To A Market Perform Hold After A Negative Eylea 2mg Biosimilar Preliminary Injunction Ruling'
Weekend Reading | Regenerative materials move towards becoming a billion-dollar giant
For a deeper understanding of how Rebirth Element has come to this day and the expected future growth.
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,230
S&P 500 Extends Winning Streak to Third Week as Materials Sector Climbs
News Highlights: Top Company News of the Day - Friday at 1 PM ET
Regeneron Pharmaceuticals Suffers Worst Month in Two Years After Legal Setback
Express News | Regeneron Pharmaceuticals Shares up 1.9% After US FDA Approves Co and Partner Sanofi's Drug to Treat 'smoker's Lung'